Long-term Management of Patients With Ruptured HCC
- Conditions
- Hepatocellular Carcinoma
- Registration Number
- NCT06505291
- Lead Sponsor
- University Hospital, Caen
- Brief Summary
The main objective of this work is to evaluate the prevalence and results of specific management of HCC after spontaneous rupture, since the arrival of sorafenib in 2008.
- Detailed Description
Retrospective, observational, multicenter study over the period from January 2008 to April 2024.
Cases had to be 18 years or older. They were identified by two different methodologies adapted to the 4 participating centers. In particular, a request for ICD10 C22.0 (CHC) codes associated with K66.1 (hemoperitoneum) was carried out by the medical information departments (DIM) of the Caen University Hospital and the Avicenne hospital. Secondly, the automated keyword selection tools "Cohort 360" and "i2b2" were used at the La Pitié Salpetrière and Paul Brousse hospital centers to identify the terms "CHC" and "ruptured" in the computerized patient files. Secondarily, duplicates and coding errors were excluded.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 112
- Ruptured hepatocellular carcinoma with or without cirrhosis
- Liver adenoma without histologically proven HCC
- Other benign or malignant liver tumors
- ATCD of potentially triggering interventional procedure in the previous month.
- Hemorrhagic ascites without tumor
- Intratumoral hemorrhages without hemoperitoneum or capsular rupture
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Survival after rupture of hepatocellular carcinoma 15 years
- Secondary Outcome Measures
Name Time Method